Constrictive Bronchiolitis: Definition and Key Features
Constrictive bronchiolitis (CB) is a histological pattern of lung injury characterized by subepithelial fibrosis of the small airways that narrows and sometimes obliterates bronchiolar lumens 1. This fibrotic and destructive process involves concentric fibrosis in the bronchiolar submucosal layer with continual external circular scarring, which may progress to complete obliteration of the bronchioles 2, 3, 4.
Pathophysiology
The disease process is limited to the membranous and respiratory bronchioles, with inflammation and fibrosis occurring predominantly in the walls and contiguous tissues of these small airways 2, 3. Critically, CB does not extend into the alveoli, distinguishing it from other bronchiolar disorders like bronchiolitis obliterans-organizing pneumonia (BOOP), which has a different histopathology and clinical course 3.
Clinical Presentation
The clinical syndrome manifests with:
- Progressive, often irreversible airflow obstruction on pulmonary function testing (typically obstructive pattern in 86% of cases) 5, 6
- Early inspiratory crackles on physical examination 4, 7
- Chest radiograph that is often normal despite significant symptoms 4
- Progressive exertional dyspnea, commonly associated with cough 6
Diagnostic Features
High-resolution CT scanning reveals characteristic findings:
- Mosaic pattern of perfusion 5, 7
- Air trapping on expiratory films 4, 7
- Bronchiolectasis and thickened small airway walls 4
A critical diagnostic pitfall: Histopathologic diagnosis can be extremely difficult due to the patchy distribution of lesions. Bronchoscopic lung biopsies are usually nondiagnostic (90% in one series), while surgical lung biopsies are far more definitive 6. In early stages, CB may be subtle and easily missed on routine hematoxylin-eosin staining; in advanced stages, the patchy scarring may be misinterpreted as nonspecific fibrosis 3.
Etiologies
CB occurs in multiple clinical contexts 1, 2, 5:
Most common causes:
- Lung and heart-lung transplantation (34-39% of patients, usually within first 2 years) - the single most important factor leading to death post-transplant 2
- Bone marrow/hematopoietic stem cell transplantation with graft-versus-host disease 5
Other established causes:
- Connective tissue diseases, particularly rheumatoid arthritis 2, 5, 6
- Inhalation of toxic agents (nitrogen dioxide, diacetyl in microwave popcorn production, burn pit exposures in military deployment) 2, 4, 8
- Certain medications (penicillamine) 2
- Viral infections in children (adenovirus, influenza A, measles, Mycoplasma pneumoniae) 2
- Consumption of Sauropus androgynus (East Asian vegetable) 2, 4
Important clinical consideration: CB can be the presenting manifestation of previously undiagnosed connective tissue disease. Nearly half of patients with cryptogenic CB manifest positive CTD serology, with some eventually diagnosed with rheumatoid arthritis, Sjögren syndrome, or undifferentiated CTD 6.
Natural History and Prognosis
The natural history of CB in nontransplant populations remains unknown and requires more data to determine prevalence 1. In lung transplant patients, the overall mortality rate is approximately 25%, though 87% of asymptomatic patients diagnosed solely by transbronchial biopsy had resolution or stabilization of disease 2. This is generally a nonsteroid-responsive lesion with progressive and often fatal airflow obstruction 4, 5.
Management Approach
Based on consensus recommendations 1:
- Comprehensive assessment of exposures should be undertaken
- Comorbidities must be addressed
- Pulmonary rehabilitation can be included in management
- Previously deployed individuals with persistent symptoms without clear diagnosis should be referred to specialty facilities with expertise in postdeployment health
Empirical treatment consists of corticosteroids and immunosuppressive agents, though response is typically poor 4. For lung transplant recipients, tacrolimus remains important for immunosuppression, extracorporeal photopheresis may improve pulmonary function decline, and azithromycin may be effective in some cases 7. For disabling disease, lung transplantation can be a successful option 4, 9.